Duopharma to supply 6.4 million doses of Sputnix V vaccine 


KUALA LUMPUR: Duopharma Biotech Bhd has entered into a deal to supply the Ministry of Health with 6.4 million doses of Covid-19 vaccine developed by Russia.

The supply is subject to the “Sputnik V” vaccine being approved by Drug Control Authority, Malaysia through technical evaluation by the National Pharmaceutical Regulatory Agency.

Start your ads-free experience now!

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Duopharma Biotech , vaccine , Sputnix V

   

Next In Business News

Shanghai shares end at two-month low as traders gauge lacklustre data
Gold subdued as investors await further data for Fed rate cues
BOJ to forgo July rate hike, taper US$152bil per year, says ex-policymaker
Oil prices slip on weaker US consumer demand, rise in China output
Thai baht declines in thin holiday trading across Asian markets
Asia shares muted on China data, euro on defensive
L'Occitane chairman Geiger offers scrip alternative to take firm private
China stocks down on weaker-than-expected data, HK shares up
China new home prices fall at fastest clip in nearly 10 years
Asia shares muted on mixed China data, euro pressure

Others Also Read